Calgary, Alberta, May 16, 2016 – Zenith Epigenetics Corp. ("Zenith" or the "Company") today announced that it has closed a private placement of 24,560,500 common shares at a price of US$1.00 per share for gross proceeds of US$24,560,500 (the "Private Placement") to Eastern Capital Limited ("Eastern"). The shares are subject to a four month hold period. After giving effect to the Private Placement, Eastern holds 47,760,500 common shares of Zenith, representing approximately 38.6 percent of Zenith's issued and outstanding common shares. Eastern also holds 2,048,640 common share purchase warrants of Zenith. Pursuant to the terms of the Private Placement, in the event that Zenith completes an equity financing within 180 days and the price per share is lower than US$1.00, the price per share paid by Eastern will be adjusted to the lower price per share and Eastern will, accordingly, receive additional common shares for no additional consideration. Furthermore, in the event that Zenith completes an equity financing within 180 days and Zenith issues or grants additional securities, contractual rights or entitlements to any of the subscribers, then Zenith shall issue or grant the same additional securities, contractual rights or entitlements to Eastern. This kind of specific day range has not been seen before when exercising private placement with both companies . In my opinion it has been keeping Resverlogix range bound for ALONG time $1.00 US or less ! ... The idea of accumulation and power for purposes of taking both companies Private seems very real to me . Zenith ultimately is in greater risk as shareholders await renal trial ( third cohort) findings of trial are expected to show tumor reduction ... My belief (opinion) Dart and groups have and continue to strangle proper companies valuation for personal gainful reasons that do not align with retail investors :(. Like to discuss with others there opinions ,,, Stock